Innovator股票定义保护主动型ETF-6个月(4月/10月) APOC 深 沪
等待开盘 11-05 09:30:00 美东时间
26.76
+0.105
+0.39%
华盛通- 最 高26.77
- 今 开26.65
- 成交量 1.75万股
- 最 低 26.65
- 昨 收 26.655
- 总市值 8563.21万
- 52周最高 26.89
- 市盈率 静 --
- 换手率 0.55%
- 52周最低 25.53
- 委 比 -60.00%
- 总股本 320.00万
- 历史最高 26.89
- 量 比 0.82
- 振 幅 0.45%
- 历史最低 24.60
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Cellectis presented preclinical data for its .HEAL-101, an in vivo base editor targeting APOC3 for severe hypertriglyceridemia. The data showed 70% human APOC3 editing and 76% triglyceride reduction after a single dose in murine models. The therapy demonstrated efficient, specific editing with liver-restricted activity. Cellectis plans to initiate a Phase 1 trial in China, with initial clinical data expected in late 2027.
10-27 07:15
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
Arrowhead Pharmaceuticals (ARWR) on Sunday said its drug plozasiran sharply reduced triglyceride levels and acute pancreatitis events in two Phase 3 studies involving patients with severe hypertriglyc...
08-31 00:30
Spire Global Selected By Amadeus IT Group To Provide Automatic Dependent Surveillance–Broadcast Data Fusion For Integration Into Amadeus Virtual Airport Operations Center
Spire's multi-source ground and space-based data fusion to power real-time aircraft visibility within Amadeus' Virtual Airport Operations Center (vAPOC)Spire Global, Inc. (NYSE:SPIR) ("Spire" or "the Company"), a global
05-19 18:48
2026开年中国创新药BD交易刷新阶段新高 瑞博生物大涨超6%
①小核酸药物技术为何近期频繁获得国际制药巨头的高额授权合作？ ②在2026年开年创新药BD交易规模已达332.8亿美元的背景下，合作热潮是否可持续？
02-12 10:13
